First-In-Human to Commercial: A Microdosing Journey

This executive summary will explore the benchmark practices for rapid progression from first–in–human to large–scale commercial manufacture for microdosing API. Xcelodose^®–based systems are an industry standard for rapid and accurate microdosing and an integral part of accelerated pathways to first–in–human studies. Utilization of the Xcelodose^® technology can increase speed to clinic and quickly assess new compounds while remaining cost–conscious. Upon successful clinical studies, scale up to large–scale manufacture has previously been a limitation. Read the executive summary to learn more.